Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07455955) titled 'Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile' on March 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).
Primary Sponsor: Chinese University of Hong Kong
Condition:
Breast Cancer
Intervention:
Drug: Standard antiemetic regimen or Olanzapine antiemetic regimen
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 3, 2026
Target Sample Size: 200
Countries of Recruitment:
Hong Kong
To know more, visit https://clinicaltrials.go...